VM (VM) News
Follow VM (VM) news in one place: company catalysts, earnings, analyst actions and wider market developments. Review 4 public stories across 3 publication days to understand how the story developed. Public news appears after a 15-minute delay; LiveCast subscribers can follow new headlines and hear important updates without this additional delay.
L
Voyageur Pharmaceuticals Ltd. (VM) To Issue Shares to Settle $192.3K Debt
Voyageur Pharmaceuticals proposes to settle $192.3K of debt by issuing shares at $0.155, including $52.3K to an officer, subject to TSXV acceptance. Shares will have a four-month-and-one-day hold.Material DetailsContext
EQUITY | Sep 24, 2026, 09:53 PM UTC
L
Voyageur Pharmaceuticals Announces Proposed Issuance of Shares for Debt
Calgary, Alberta--(. - September 24, 2026) - Voyageur Pharmaceuticals Ltd. TSXV:VM (OTC Pink: VYYRF) ("Voyageur" or the "Company"), Canadian developer of pharmaceutical-grade barium and iodine contrast media for medical
EQUITY | Sep 24, 2026, 09:52 PM UTC
L
Voyageur Pharmaceuticals secures $1 million on first Bayer milestone
Voyageur Pharmaceuticals Ltd. said it achieved its first milestone under a non-dilutive Bayer collaboration, securing a $1 million payment.
EQUITY | Sep 10, 2026, 01:30 PM UTC
L
Voyageur Pharmaceuticals hits first feasibility-study milestone, receives $1 million
Voyageur Pharmaceuticals Ltd. said it achieved the first milestone on its feasibility study for iodine production and secured a $1 million payment.
EQUITY | Sep 09, 2026, 11:30 AM UTC